Abstract：【Objective】To investigate the effects of long-term use of adefovir dipivoxil (ADV) on renal functions in patients of chronic hepatitis B (CHB).【Methods】A total of 317 patients with CHB who were treated with ADV (10 mg/d) alone or combined with oral administration of for more than 24 months were selected and divided into kidney injury group (118 cases)and non renal injury group (199 cases)according to the renal function damage.Serological, virological and renal function tests in the past two years were analyzed. By χ2 test, Binary Logistic Regression Analysis, ROC curve analysis and other statistical methods, the effects of elements including the gender, age, time of use ADV, ADV combined with other antiviral drugs, HBsAg, HBeAg, HBV, DNA, ALT, GLU and other factors on early renal injury were accordingly investigated.【Results】Chi-square test showed that: there was significant difference in age and ADV medication time, but there was no significant difference between the other factors; Binary Logistics Regression Analysis showed that: age and ADV medication time had significant effect on the dependent variable of early renal damage; ROC curve analysis showed that: age and ADV duration had a significant corresponding sensitivity on early renal injury, the relevant Youden's index was 0.616, 0.422.【Conclusion】Age and treatment time of ADV are risk factors of renal damage incidents; the age of 47.5 years old can be used as a critical reference year of kidney damage events; the time of ADV medication is 3.175 years, which can be used as the critical reference life events of early renal injury occurred.
张鹏,张长江,朱研,鲜耀国,王小红. 阿德福韦酯长期应用对慢性乙型肝炎患者肾功能的影响[J]. 医学临床研究, 2017, 34(10): 1873-1876.
ZHANG Peng, ZHANG Chang-jang, ZHU Yan, et al. Effects of Long-term Use of Adefovir Dipivoxil on Renal Functions in Patients of Chronic Hepatitis B. JOURNAL OF CLINICAL RESEARCH, 2017, 34(10): 1873-1876.
[1]Hong-Yu,Jia,Feng,Ding,Jian-Yang,et al.Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B[J].World J Gastroenterol,2015,(12):3657-3662. [2]朱敏芳,奚骏,胡晓凤.阿德福韦酯对慢性乙型肝炎老年患者的肾脏毒性分析[J].上海医药,2016,(18):30-31,56. [3]Shimizu M,Furusyo N,Ikezaki H,et al.Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B[J].World J Gastroenterol,2015,21(7):2116-2123. [4]许亚辉.肾脏早期损伤诊断标志物的研究现状[J].山西医药杂志,2014,(14):1666-1667. [5]JIANG Wei,LIU Tuo,DONG Hui,et al.Relationship between serum DNA replication,clinicopathological characteristics and prognosis of hepatitis B virus-associated glomerulonephritis with severe proteinuria by Lamivudine plus Adefovir Dipivoxil combination therapy[J].Biomed Environ Sci(Engl),2015,28(3):206-213. [6]EI Pour.Adefovir as a Novel Drug for the treatment of chronic hepatitis B in patients with end-stage renal disease and kidney recipients[J].Hepatitis Monthly,2008,8(2):135-139. [7]Kamar N,Huart A,Tack I,et al.Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.[J].Clin Nephrol,2009,71(1):36-42. [8]杨晓艳.阿德福韦酯治疗慢性乙型肝炎引发低磷血症的临床研究[D].郑州大学,2016. [9]丁丰.慢性乙肝患者阿德福韦酯长期治疗的早期肾脏损害研究[D].浙江大学,2016. [10]程辉,袁宇慧.不同核苷(酸)类抗病毒药物在失代偿期乙型肝炎肝硬化患者治疗中的应用[J].安徽医药,2016,(12):2327-2331. [11]陈玉兰,刘洁,陈立宇.三种核苷类似物对慢性乙型肝炎患者肾功能影响的长期随访研究[J].解放军医药杂志,2016,(06):83-86. [12]孙予州.阿德福韦酯的不良反应分析[J].中国现代药物应用,2014,(24):10-12. [13]Yap DY,Chan TM.Evolution of hepatitis B management in kidney transplantation[J].World J Gastroenterol,2014,(2):468-474. [14]Yun TJ,Jung JY,Kim CH,et al Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B[J].World J Gastroenterol,2012,18(47):6987-6995. [15]Lampertico P,ViganòM,Facchetti F,et al.Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B.[J].Nephrol Dial Transplant,2011,26 (6):2037-2041. [16]茅益民,曾民德,张韡,等.阿德福韦酯治疗中国慢性乙型肝炎患者二年的肾脏安全性分析[J].中华临床感染病杂志,2014,(2):121-124. [17]朱敏芳,奚骏,胡晓凤,等.阿德福韦酯对慢性乙型肝炎老年患者的肾脏毒性分析[J].上海医药,2016,37(18):30-31,56.
2017, Vol. 34 
